TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06246565
Drug: HS-10383 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-10383 administered as one 50 mg, 100 mg 200 mg tablet once daily, depending upon randomization.
Study: NCT06490913
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2, bid, d1-d14，q3w，1cycle
Study: NCT06490913
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg/m2, d1,q2w
Study: NCT05727644
Drug: NNC0194-0499
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single subcutaneous injection of 30 mg NNC0194-0499.
Study: NCT06022237
Drug: Ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 150 mg once monthly.
Study: NCT06022237
Drug: Calcium
Normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 500 mg twice daily
Study: NCT05506007
Drug: DA-5216-R
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the cross-over \[Part A\], patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence I. Single dose of DA-5216-R(Fasting) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8.~* Sequence II. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216-R(Fasting) on Day 8.
Study: NCT06035354
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection once a week.
Study: NCT06265675
Drug: Phenol
Normalized name: Phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemical neurolysis
Study: NCT06035354
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection every 2 weeks for 16 weeks then crossover to AK120 Regimen 4 and Regimen 5.
Study: NCT06510816
Drug: ANX007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form: solution for injection; Route of Administration: IVT injection
Study: NCT05284409
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 patients will receive 15 mg/kg Acetaminophen IVI
Study: NCT06501053
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (900 mg/m2 bid, on radiation days)
Study: NCT05099133
Drug: LEO 138559
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LEO 138559 is an antibody given by injection just under the skin.
Study: NCT05967299
Drug: ZMA001 (BC-NKA-20008)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZMA001 is a fully human, monoclonal antibody (IgG1) that inhibits migration of activated monocytes and macrophages and reduces pulmonary vascular remodeling and pulmonary artery pressure in pre-clinical rodent models of pulmonary arterial hypertension (PAH).
Study: NCT05005806
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo soft gel
Study: NCT05790382
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution for infusion
Study: NCT05776121
Drug: ZB001 for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Cohort1 (3 mg/kg) ZB001 four IV injections
Study: NCT05776121
Drug: ZB001 for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Cohort2 (10 mg/kg) ZB001 four IV injections
Study: NCT05112536
Drug: Cylophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide administered IV every 2 weeks for the first 4 cycles (1-4), each cycle 2 weeks in length.
Study: NCT05112536
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin administered as an IV bolus every 2 weeks for the first 4 cycles (1-4), each cycle 2 weeks in length.
Study: NCT05111444
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m\^2 as oral capsules BID on Days 1-14 of each 3-week cycle, administered as part of XELOX chemotherapy regimen
Study: NCT06126263
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive antitoxin therapy
Study: NCT00199277
Drug: i.v. iron sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00199277
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04972396
Drug: Ethinylestradiol and Levonorgestrel
Normalized name: Ethinylestradiol and levonorgestrel only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken by mouth (PO)
Study: NCT06144918
Drug: SBI-100 Ophthalmic Emulsion, 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% (5 mg/mL) SBI-100 Ophthalmic Emulsion eyedrop
Study: NCT06144918
Drug: SBI-100 Ophthalmic Emulsion, 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0% (10 mg/mL) SBI-100 Ophthalmic Emulsion eyedrop
Study: NCT06144918
Drug: SBI-100 Ophthalmic Emulsion, Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, SBI-100 Ophthalmic Emulsion eyedrop without the active ingredient (SBI-100)
Study: NCT06278077
Drug: Neurexan
Normalized name: Coffea arabica/Common Oat/Passiflora incarnata/Zincum Valerianicum 12 X/0.6 MG-2 X/0.6 MG-2 X/0.6 MG-4 X/0.6 MG Sublingual Tablet [NEUREXAN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active ingredients are Passiflora incarnata Dil. D2 (0.6 mg / tablet), Avena sativa Dil. D2 (0.6 mg / tablet), Coffea arabica Dil. D12 (0.6 mg/tablet) and Zincum isovalerianicum Dil. D4 (0.6 mg / tablet). Inactive excipients are lactose monohydrate and magnesium stearate.
Study: NCT06278077
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contains lactose monohydrate, magnesium stearate and looks identical to Neurexan in terms of taste, size, color and labelling.
Study: NCT06535568
Drug: Single antiplatelet therapy (SAPT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The antithrombotic regimen is single antiplatelet therapy (SAPT). The Investigator will decide if to use aspirin or clopidogrel, whereas ticagrelor or prasugrel are not recommended in our study population since no benefit (or even harm) has been shown by these drugs in head-to-head trials versus clopidogrel in elderly PCI populations. The type of agent and treatment duration will be selected according to the clinical characteristics of the patient.
Study: NCT05113693
Drug: CKD-501, D759, H053
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT05155202
Drug: Antihypertensive Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of intravenous Nicardipine or Urapidil
Study: NCT04678882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
Study: NCT04579523
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05137067
Drug: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05137067
Drug: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
Study: NCT06698549
Drug: ALG-097558
Normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of ALG-097558 300 mg (3 x 100 mg tablets)
Study: NCT05182463
Drug: Nucleoside Analogs
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleos(t)ide analogs refer to one of the first-line drugs, including ETV, TDF and TAF.
Study: NCT05879653
Drug: MK-3475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the induction phase, MK-3475 200 mg will be administered as four cycles of 3-weeks regimen, with ASG-22CE 1.25 mg/kg administered on Day 1 and Day 8 of each cycle. The treatment and maintenance phases will consist of 9 cycles of one course per 6 weeks, with MK-3475 400 mg administered on Day 1 of each course at Q6W.
Study: NCT05879653
Drug: ASG-22CE
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the induction phase, four cycles of 3-weeks regimen are administered, with ASG-22CE 1.25 mg/kg administered on Day 1 and Day 8 of each cycle.
Study: NCT05722782
Drug: Piroxicam
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with 20 mg piroxicam per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment
Study: NCT05722782
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with 1000 mg Acetaminophen per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment
Study: NCT05722782
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with placebo per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment
Study: NCT05565742
Drug: LY3819469
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05565742
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05970640
Drug: Placebo matching BI 3006337
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 3006337
Study: NCT06383078
Drug: HR070803
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR070803 60 mg/\^2 D1 over 90 minutes.
Study: NCT06660290
Drug: 0.003% AR-15512 ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational ophthalmic solution for topical instillation
Study: NCT06660290
Drug: REFRESH® Classic ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially available ophthalmic solution for topical instillation
Study: NCT06166498
Drug: SP (Macleods Pharmaceuticals Ltd)
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children who weigh \<10kg will receive Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets; children who weigh \>10kg will receive 500mg sulfadoxine plus 25mg pyrimethamine
Study: NCT04551261
Drug: RTV
Normalized name: Accu-Chek SmartView Test Strips
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. It is HIV protease inhibitors indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection;~2. It is a CYP3A inhibitor combined with other drug to increase the exposure in human.
Study: NCT04551261
Drug: TAF
Normalized name: Altafed
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor and is indicated for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease.
Study: NCT06196515
Drug: Calcium hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
Study: NCT06196515
Drug: nano calcium hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
Study: NCT06492122
Drug: [225Ac]Ac-FL-020
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[225Ac\]Ac-FL-020 injected intravenously
Study: NCT06492122
Drug: Blood samples for PK
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following the first injection of \[225Ac\]Ac-FL-020, blood samples after treatment will be collected for PK evaluation.
Study: NCT06492122
Drug: [111In]In-FL-020
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose of \[111In\]In-FL-020 will be injected prior to the first dose of \[225Ac\]Ac-FL-020 for dosimetry evaluation
Study: NCT04866563
Drug: AX-8, Part 1 of the study
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally disintegrating tablets, BID
Study: NCT04866563
Drug: Placebo, Part 1 of the study
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally disintegrating tablets, BID
Study: NCT04866563
Drug: AX-8, Part 2 of the study
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally disintegrating tablets, TID
Study: NCT04866563
Drug: Placebo, Part 2 of the study
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally disintegrating tablets, TID
Study: NCT05839470
Drug: leucovorin or levoleucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: leucovorin 400 or levoleucovorin 200 mg/m² iv continue for 2 hours
Study: NCT04666714
Drug: Praga formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praga formulation tablet
Study: NCT04945070
Drug: IGlarLixi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching T2DM subjects from MDI to iGlarLixi
Study: NCT04721795
Drug: Standard anti tuberculosis drugs only
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight
Study: NCT04564339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosages (loading and maintenance) will be based on the participant's body weight.
Study: NCT04881461
Drug: 5-grass mix SLIT-drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual allergy immunotherapy drops, for daily administration
Study: NCT04881461
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04937387
Drug: FF/UMEC/VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/UMEC/VI will be administered.
Study: NCT04484142
Drug: DS-1062a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-1062a will be administered as an intravenous (IV) infusion once every 3 weeks
Study: NCT06441097
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
Study: NCT06441097
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
Study: NCT00001014
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06254274
Drug: RAY1225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06254274
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05023486
Drug: Anti-PD-1 Therapy
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: previously initiated per standard of care, at a dose and frequency in accordance with the package insert
Study: NCT05598333
Drug: AB-1002
Normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary Infusion of AB-1002 or placebo
Study: NCT04719650
Drug: Zoledronic Acid Injection
Normalized name: zoledronic acid Injection
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Infusion 1mg zoledronic acid once.
Study: NCT04719650
Drug: Zoledronic Acid Injection
Normalized name: zoledronic acid Injection
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Infusion 2.5mg zoledronic acid once.
Study: NCT04719650
Drug: Zoledronic Acid Injection
Normalized name: zoledronic acid Injection
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Infusion 5mg zoledronic acid once.
Study: NCT04719650
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion normal saline once.
Study: NCT04904120
Drug: [203Pb]VMT01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnostic imaging radiopharmaceutical; by intravenous infusion
Study: NCT04904120
Drug: [68Ga]VMT02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnostic imaging radiopharmaceutical; by intravenous infusion
Study: NCT04939597
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05062200
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered as an oral tablet.
Study: NCT06178523
Drug: Clomiphene Citrate.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene Citrate (Clomid®) 100 mg for 5 days starting from the second day of the menstrual cycle (Groups A, B, and C).
Study: NCT06006247
Drug: CVN424 150 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 1 CVN424 tablet (150 mg) per day.
Study: NCT06006247
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 1 matching placebo tablet per day.
Study: NCT05038020
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo
Study: NCT04661709
Drug: WXG placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one dose daily, two times per day.
Study: NCT04262687
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2000 mg/m²/day, from day 1 to 14 of each cycle
Study: NCT06451783
Drug: Celecoxib capsule
Normalized name: Celecoxib Capsules
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Celecoxib Capsules, 200mg per dose, once daily after lunch.
Study: NCT06024642
Drug: V117957
Approvals — FDA: no, EMA: no, PMDA: no
Description: V117957 1 mg - 1 tablet taken orally at bedtime.
Study: NCT06024642
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match V117957 tablets - 1 tablet taken orally at bedtime.
Study: NCT06548919
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: All endocrine treatment regimens approved for advanced breast cancer, including tamoxifen, aromatase inhibitors, fulvestrant, etc.
Study: NCT05639127
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulization of prednisolone
Study: NCT00025051
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05203497
Drug: SPECT
Normalized name: Spectrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single injection of 99mTc-ZHER2:41071, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
Study: NCT06563271
Drug: Dexketoprofen Trometamol 50 Mg/mL Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen 50 mg administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).
Study: NCT06563271
Drug: Ibuprofen 100 MG/ML Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 100 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).~Group P: Paracetamol 10 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).
Study: NCT06563271
Drug: Paracetamol 10 Mg/mL Solution for Injection
Normalized name: Paracetamol 10 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 10 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).
Study: NCT06563271
Drug: isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen and dexketoprofen will be administered intravenously (IV) by mixing them into 150 cc of isotonic saline.
Study: NCT05240911
Drug: Levothyroxine Sodium Tablets
Normalized name: Levothyroxine Sodium Tablets
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For patients in experimental group, initial levothyroxine dose is calculated through the Poisson regression model; and for patients in comparator group, initial levothyroxine dose is calculated through 1.6 ug/kg/d.
Study: NCT05528354
Drug: VEN and DEC based conditioning regimen
Normalized name: Apis mellifera ven protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with age\<50 years and HCT-CI\<3:~Haploidentical transplantation: AraC 2g/m2 d-10\~d-9, BU 0.8mg/kg q6h d-8\~-6, CTX 1.8g/m2 d-5\~d-4, Meccnu 250mg/m2 d-3, ATG 1.5mg/kg/d d-5\~-2, VEN 400mg/d d-15\~-9, DEC 20mg/m2 d-15\~-11; HLA-matched transplantation: BU 0.8mg/kg q6h d-7\~-4, CTX 60mg/kg d-3\~d-2, Meccnu 250mg/m2 d-1, VEN d-12\~-8, DEC 20mg/m2 d-12\~-6, and ATG for the unrelated donor type.~Patients with age\>50 years or HCT-CI≥3:~Flu 30mg/m2 d-10\~-5, BU 0.8mg/kg q6h d-7\~-5, Meccnu 250mg/m2 d-4, ATG 7.5mg/kg divided into d-4\~-1, VEN d-15\~-9, DEC 20mg/m2 d-15\~-11.~Note: if Voriconazole or Posaconazole is used to prevent or treat fungal infections, VEN should be 200mg/d for 7 consecutive days.
Study: NCT05748977
Drug: SABA SAMA ICS Vs LABA LAMA ICs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short acting agents,long acting agents ,ics
Study: NCT04887480
Drug: Dianeal PD-2 with 2.5% Dextrose
Normalized name: Dianeal PD-2 with 2.5% Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800mL to 1000mL of Dianeal PD-2 into Abthera™ and dwell for 1 hour.
Study: NCT04688736
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The tablet resembles chlorpheniramine but has no therapeutic value.
Study: NCT05133817
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of normal saline by IV infusion.
Study: NCT05133817
Drug: Norepinephrine (0.025 μg/kg/min)
Normalized name: mepivacaine 0.025 MG/ML / norepinephrine 30 MG/ML Injectable Solution
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
Study: NCT05133817
Drug: Norepinephrine (0.05 μg/kg/min)
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.